IDiyas

For the Inventor, By the Inventor

Waltham, MA, United States of America

Ruoxi Lan

USPTO Granted Patents = 37 

 

 

Average Co-Inventor Count = 6.0

ph-index = 7

Forward Citations = 135(Granted Patents)


Location History:

  • Fleurimont, CA (2007 - 2015)
  • Arlington, MA (US) (2008 - 2016)
  • Waltham, MA (US) (2013 - 2020)

Company Filing History:

goldMedal30 out of 2,937 
 
Merck Patent Gmbh
 patents
silverMedal5 out of 19 
 
Tranzyme Pharma Inc.
 patents
bronzeMedal2 out of 26 
 
Ocera Therapeutics, Inc.
 patents

Years Active: 2007-2020

Loading Chart...
Loading Chart...
Loading Chart...
37 patents (USPTO):Explore Patents
1. 10836750 - TLR7/8 antagonists and uses thereof (2020-11-17),
2. 10793553 - TLR7/8 antagonists and uses thereof (2020-10-06),
3. 10517872 - Pyridazinone macrocycles as IRAK inhibitors and uses thereof (2019-12-31),
4. 10392375 - Heteroaryl compounds as IRAK inhibitors and uses thereof (2019-08-27),
5. 10287300 - Heterocyclic derivatives as modulators of kinase activity (2019-05-14),
6. 10233160 - Substituted pyrido[3,4-d]pyrimidines and pyrido[4,3-d]pyrimidines as p70S6K inhibitors (2019-03-19),
7. 10080753 - Heterocyclic carboxamides as modulators of kinase activity (2018-09-25),
8. 10080750 - Aminopyrimidine derivatives for use as modulators of kinase activity (2018-09-25),
9. 10059701 - Heteroaryl compounds as IRAK inhibitors and uses thereof (2018-08-28),
10. 9981925 - Substituted benzo[d][1,2,3]triazines as p70S6K inhibitors (2018-05-29),
11. 9969710 - Heteroaryl compounds as IRAK inhibitors and uses thereof (2018-05-15),
12. 9867826 - Heterocycles as modulators of kinase activity (2018-01-16),
13. 9850255 - Heterocyclic derivatives as modulators of kinase activity (2017-12-26),
14. 9815836 - Macrocyclic compounds as IRAK1/4 inhibitors and uses thereof (2017-11-14),
15. 9708324 - Macrocyclic compounds as IRAK1/4 inhibitors and uses thereof (2017-07-18),

Title: Ruoxi Lan: Innovator in TLR7/8 Antagonist Patents

Introduction

Ruoxi Lan is a distinguished inventor based in Waltham, MA, USA, known for his significant contributions to the field of pharmaceutical innovations. With a remarkable portfolio of 30 patents, Lan focuses on advancements in TLR7/8 antagonists, presenting valuable compounds and compositions for potential therapeutic applications.

Latest Patents

Among his latest patents, Lan has developed groundbreaking compounds referred to as TLR7/8 antagonists. These compounds, formulated as Formula I, are characterized as pharmaceutically acceptable compositions, identified for their utility as TLR7/8 antagonists. These inventions promise vital implications in the treatment of various diseases, addressing critical needs in the healthcare sector.

Career Highlights

Ruoxi Lan is currently associated with Merck Patent GmbH, where he leverages his expertise in pharmacology and patent law to enhance the company’s innovation pipeline. His impressive collection of patents showcases his commitment to advancing scientific research and developing new therapeutic solutions.

Collaborations

Lan collaborates with notable colleagues, including Xiaoling Chen and Bayard R Huck, contributing to a dynamic research environment that fosters creativity and innovation in drug development. Together, they explore various avenues to optimize pharmaceutical compositions and improve patient outcomes.

Conclusion

Ruoxi Lan stands out as a pivotal figure in the realm of pharmaceutical innovation, with a wealth of patents to his name. His work on TLR7/8 antagonists illustrates his dedication to advancing medical research and the development of effective treatments, making a significant contribution to the healthcare industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…